Show simple item record

dc.contributor.authorShi, Diana D
dc.contributor.authorGuo, Jimmy A
dc.contributor.authorHoffman, Hannah I
dc.contributor.authorSu, Jennifer
dc.contributor.authorMino-Kenudson, Mari
dc.contributor.authorBarth, Jaimie L
dc.contributor.authorSchenkel, Jason M
dc.contributor.authorLoeffler, Jay S
dc.contributor.authorShih, Helen A
dc.contributor.authorHong, Theodore S
dc.contributor.authorWo, Jennifer Y
dc.contributor.authorAguirre, Andrew J
dc.contributor.authorJacks, Tyler
dc.contributor.authorZheng, Lei
dc.contributor.authorWen, Patrick Y
dc.contributor.authorWang, Timothy C
dc.contributor.authorHwang, William L
dc.date.accessioned2023-02-23T18:42:05Z
dc.date.available2023-02-23T18:42:05Z
dc.date.issued2022
dc.identifier.urihttps://hdl.handle.net/1721.1/148200
dc.description.abstractWith increasing attention on the essential roles of the tumour microenvironment in recent years, the nervous system has emerged as a novel and crucial facilitator of cancer growth. In this Review, we describe the foundational, translational, and clinical advances illustrating how nerves contribute to tumour proliferation, stress adaptation, immunomodulation, metastasis, electrical hyperactivity and seizures, and neuropathic pain. Collectively, this expanding knowledge base reveals multiple therapeutic avenues for cancer neuroscience that warrant further exploration in clinical studies. We discuss the available clinical data, including ongoing trials investigating novel agents targeting the tumour-nerve axis, and the therapeutic potential for repurposing existing neuroactive drugs as an anti-cancer approach, particularly in combination with established treatment regimens. Lastly, we discuss the clinical challenges of these treatment strategies and highlight unanswered questions and future directions in the burgeoning field of cancer neuroscience.en_US
dc.language.isoen
dc.publisherElsevier BVen_US
dc.relation.isversionof10.1016/S1470-2045(21)00596-9en_US
dc.rightsCreative Commons Attribution-NonCommercial-NoDerivs Licenseen_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/en_US
dc.sourcePMCen_US
dc.titleTherapeutic avenues for cancer neuroscience: translational frontiers and clinical opportunitiesen_US
dc.typeArticleen_US
dc.identifier.citationShi, Diana D, Guo, Jimmy A, Hoffman, Hannah I, Su, Jennifer, Mino-Kenudson, Mari et al. 2022. "Therapeutic avenues for cancer neuroscience: translational frontiers and clinical opportunities." Lancet Oncology, 23 (2).
dc.contributor.departmentMassachusetts Institute of Technology. Department of Biology
dc.contributor.departmentKoch Institute for Integrative Cancer Research at MIT
dc.contributor.departmentHarvard University--MIT Division of Health Sciences and Technology
dc.relation.journalLancet Oncologyen_US
dc.eprint.versionAuthor's final manuscripten_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dc.date.updated2023-02-23T18:24:24Z
dspace.orderedauthorsShi, DD; Guo, JA; Hoffman, HI; Su, J; Mino-Kenudson, M; Barth, JL; Schenkel, JM; Loeffler, JS; Shih, HA; Hong, TS; Wo, JY; Aguirre, AJ; Jacks, T; Zheng, L; Wen, PY; Wang, TC; Hwang, WLen_US
dspace.date.submission2023-02-23T18:24:27Z
mit.journal.volume23en_US
mit.journal.issue2en_US
mit.licensePUBLISHER_CC
mit.metadata.statusAuthority Work and Publication Information Neededen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record